These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18922853)

  • 1. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
    Yong AS; Keyvanfar K; Hensel N; Eniafe R; Savani BN; Berg M; Lundqvist A; Adams S; Sloand EM; Goldman JM; Childs R; Barrett AJ
    Blood; 2009 Jan; 113(4):875-82. PubMed ID: 18922853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
    Heaney NB; Pellicano F; Zhang B; Crawford L; Chu S; Kazmi SM; Allan EK; Jorgensen HG; Irvine AE; Bhatia R; Holyoake TL
    Blood; 2010 Mar; 115(11):2241-50. PubMed ID: 20068223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
    Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
    Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.
    Savani BN; Mielke S; Adams S; Uribe M; Rezvani K; Yong AS; Zeilah J; Kurlander R; Srinivasan R; Childs R; Hensel N; Barrett AJ
    Leukemia; 2007 Oct; 21(10):2145-52. PubMed ID: 17673900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation.
    Ureshino H; Shindo T; Sano H; Kubota Y; Ando T; Kidoguchi K; Kusaba K; Itamura H; Kojima H; Kusunoki Y; Miyazaki Y; Kojima K; Tanaka H; Saji H; Oshima K; Kimura S
    Int J Hematol; 2020 May; 111(5):733-738. PubMed ID: 31873846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.
    Holyoake TL; Jiang X; Jorgensen HG; Graham S; Alcorn MJ; Laird C; Eaves AC; Eaves CJ
    Blood; 2001 Feb; 97(3):720-8. PubMed ID: 11157490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
    Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
    Cancer Res; 2006 Jul; 66(14):7317-25. PubMed ID: 16849582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
    Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
    Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.
    Kuroda I; Inukai T; Zhang X; Kikuchi J; Furukawa Y; Nemoto A; Akahane K; Hirose K; Honna-Oshiro H; Goi K; Kagami K; Yagita H; Tauchi T; Maeda Y; Sugita K
    Oncogene; 2013 Mar; 32(13):1670-81. PubMed ID: 22665066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein.
    Yong AS; Stephens N; Weber G; Li Y; Savani BN; Eniafe R; Keyvanfar K; Kurlander R; Rezvani K; Barrett AJ
    Leukemia; 2011 Apr; 25(4):629-37. PubMed ID: 21252986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.
    Nievergall E; Ramshaw HS; Yong AS; Biondo M; Busfield SJ; Vairo G; Lopez AF; Hughes TP; White DL; Hiwase DK
    Blood; 2014 Feb; 123(8):1218-28. PubMed ID: 24363400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.
    Yong AS; Keyvanfar K; Eniafe R; Savani BN; Rezvani K; Sloand EM; Goldman JM; Barrett AJ
    Leukemia; 2008 Sep; 22(9):1721-7. PubMed ID: 18548092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
    Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R
    Blood; 2009 Dec; 114(25):5191-200. PubMed ID: 19855080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia.
    Tanturli M; Giuntoli S; Barbetti V; Rovida E; Dello Sbarba P
    PLoS One; 2011 Feb; 6(2):e17008. PubMed ID: 21347297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.
    Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH
    Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase-9 was involved in the immuno-modulatory defect of mesenchymal stem cell from chronic myeloid leukemia patients.
    Zhu XS; Shi W; An GY; Zhang HM; Song YG; Li YB
    Chin Med J (Engl); 2011 Aug; 124(16):2423-30. PubMed ID: 21933581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.
    Sconocchia G; Lau M; Provenzano M; Rezvani K; Wongsena W; Fujiwara H; Hensel N; Melenhorst J; Li J; Ferrone S; Barrett AJ
    Blood; 2005 Nov; 106(10):3666-72. PubMed ID: 16046526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe functional alterations in vitro in CD34(+) cell subpopulations from patients with chronic myeloid leukemia.
    Chávez-González A; Rosas-Cabral A; Vela-Ojeda J; González JC; Mayani H
    Leuk Res; 2004 Jun; 28(6):639-47. PubMed ID: 15120942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.